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Objective: Nonalcoholic fatty liver disease (NAFLD) and sarcopenia, which are common
in elderly men, are known as risk factors of fracture. However, few studies have examined
the association with fracture in these patients. Therefore, we aimed to investigate the
association between NAFLD with or without sarcopenia and 10-year fracture probability in
Korean men aged ≥50 years.
Materials and Methods: Data of 2,525 individuals from the 2010–2011 Korea National
Health and Nutrition Examination Survey were analyzed. NAFLD was defined using the
fatty liver index (FLI) and comprehensive NAFLD score (CNS), and liver fibrosis using the
fibrosis 4 calculator. Sarcopenia was defined as the lowest quintile for sex-specific
sarcopenia index cutoff; values. The Fracture Risk Assessment (FRAX) tool was used to
predict the 10-year probability of major osteoporotic and hip fractures.
Results: Compared to the no NAFLD group, the 10-year major osteoporotic fracture
probability was significantly associated with the FLI-defined (b = 0.16, P = 0.002) and
CNS-defined (b = 0.20, P < 0.001) NAFLD groups with liver fibrosis. Similarly, the 10-year
hip fracture probability was significantly associated with the FLI- and CNS-defined NAFLD
with liver fibrosis groups compared to the group without NAFLD (FLI-defined group, b =
0.04, P = 0.046; CNS-defined group, b = 0.05, P = 0.048). Furthermore, in the group with
sarcopenia, the 10-year major osteoporotic fracture probability was significantly
associated with the FLI- and CNS-defined NAFLD with liver fibrosis groups compared
to the group without NAFLD (FLI-defined group, b = 0.29, P = 0.003; CNS-defined group,
b = 0.38, P < 0.001).
Conclusions: NAFLD with liver fibrosis is significantly associated with a higher 10-year
major osteoporotic and hip fracture probability in Korean men aged ≥50 years, and thisn.org March 2021 | Volume 12 | Article 5993391
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Frontiers in Endocrinology | www.frontiersipositive association was more profound in patients with sarcopenia. Therefore, screening
middle-aged to elderly men who have NAFLD combined with liver fibrosis and sarcopenia
may help prevent fractures.Keywords: nonalcoholic fatty liver disease, liver fibrosis, sarcopenia, 10-year fracture probability, fracture risk
assessment toolINTRODUCTION
Fractures not only reduce the quality of life, but also increase
medical and health care cost, thereby imposing a significant
financial and socioeconomic burden (1). Therefore, it is
important to predict and prevent fractures. Currently, the
Fracture Risk Assessment (FRAX), which is a country-specific
instrument developed by the World Health Organization
(WHO), is the most widely used fracture prediction tool for
individuals aged > 40 years (2). In FRAX, the 10-year probability
of both major osteoporotic and hip fractures can be calculated by
inputting ten clinical risk factors for fracture (2). Based on
FRAX, 37.7% of menopausal women and 12.7% of men aged
over 50 years in South Korea are at high risk of osteoporotic
fracture (3). Another study also found that South Korean women
and men have an average of 59.5% and 23.8% risk of osteoporotic
fractures, respectively, in their lifetime (4).
Nonalcoholic fatty liver disease (NAFLD) is one of the most
common chronic liver diseases. It initially manifests as mild
steatosis or nonalcoholic steatohepatitis, but can progress to liver
fibrosis, end-stage liver disease with cirrhosis, and hepatocellular
carcinoma (5). The incidence of NAFLD is constantly increasing,
and it is associated with liver-related morbidity and mortality (1).
NAFLD is considered a hepatic manifestation of metabolic
syndrome. It is associated with various metabolic abnormalities
and may be associated with an increased risk of fractures (6).
However, evidence on the association between NAFLD and bone
mineral density (BMD) are conflicting (7). Most studies
investigating this association with BMD have targeted mild
liver steatosis (8), and few studies have evaluated patients with
advanced NAFLD, such as nonalcoholic steatohepatitis (9).
Furthermore, there is no direct analysis of the association
between NAFLD and fracture using the FRAX tool.
The prevalence of NAFLD is twice as high in men than in
women (10), and one study also reported that NAFLD and
sarcopenia often co-occur in elderly patients (11). Sarcopenia is
associated with decreased bone density and loss of muscle mass,
thus making it a risk factor for osteoporotic fracture and a
predisposing factor for falls (12). A systematic review also
reported that sarcopenia was independently associated with
NAFLD and, possibly, advanced fibrosis (13). Therefore, we
focused on the effect of NAFLD with liver fibrosis and
sarcopenia on the 10-year fracture probability evaluated using
the FRAX tool in middle-aged to elderly Korean men. One study
that evaluated the 10-year fracture probability using the FRAX
tool showed that such probability was increased in middle-aged
Korean women with metabolic syndrome (14). However, to the
best our knowledge, the 10-year fracture probability evaluatedn.org 2using FRAX tool has not been investigated in patients with
NAFLD, liver fibrosis, and sarcopenia. In this study, we
hypothesized that NAFLD is significantly associated with a
higher 10-year fracture probability, and this association are
more profound in patients with sarcopenia. Therefore, we
aimed to investigate the association between 10-year fracture
risk and NAFLD with or without sarcopenia in Korean men
aged ≥50 years, using data from the Korea National Health and
Nutrition Examination Survey (KNHANES).MATERIALS AND METHODS
Study Population and Design
This cross-sectional study used data from the 2010–2011
KNHANES. The KNHANES is a nationwide population-based
survey conducted by the Korean Ministry of Health and Welfare
and the Division of Chronic Disease Surveillance of the Korean
Centers for Disease Control and Prevention.
Among the 17,476 subjects of the 2010–2011 KNHANES, 2,915
men aged ≥50 years were initially evaluated. Of them, we excluded
191 patients with physician-diagnosed hepatitis B, hepatitis C, liver
cirrhosis, hepatocellular carcinoma, and rheumatoid arthritis,
which is risk factor for fracture and patients who were high-risk
drinkers (> 210 g per week for men and > 140 g per week for
women). From the remaining 2,724 patients, those with missing
data on factors needed for calculating the fatty liver index (FLI),
comprehensive NAFLD score (CNS), fibrosis 4 calculator (FIB-4),
and FRAX were further excluded. Finally, 2,525 subjects were
included in the final analysis (Figure 1).
All participants provided written informed consent before
participation in the study, and the KNHANES was conducted
following ethical approval by the Institutional Review Board of
the Korea Centers for Disease Control and Prevention (No.
2010-02CON-21-C, 2011-02CON-06C). The protocol of the
current study was approved by the Institutional Review Board
of Yonsei University, Seoul, Korea (No. 4-2020-0744).
Data Collection
Subjects were interviewed by trained staff using standardized
health questionnaires, which included questions on demographic
information, medical history of osteoporosis diagnosis or
fracture, parental history of fracture, history of smoking, and
alcohol intake. In our study, the variables used in the FRAX tool
to predict the 10-year probability of major osteoporotic fracture
(spine, forearm, hip, or shoulder fractures) and hip fracture (2)
were considered when adjusting for the risk factors. The variables
included age, sex, previous history of fracture, parental history ofMarch 2021 | Volume 12 | Article 599339
Lee et al. 10-Year Fracture Probability and NAFLDhip fracture, prevalence of rheumatoid arthritis, secondary
osteoporosis, use of steroids, current smoking, drinking more
than 3 units per day, body weight, height, and bone mineral
density of the femoral neck (2). Anthropometric measurements
and laboratory tests were also conducted.Frontiers in Endocrinology | www.frontiersin.org 3NAFLD was defined using FLI and CNS, and liver fibrosis
using FIB-4. The FLI model was calculated using four variables:
body mass index (BMI), waist circumference, serum triglycerides
(TG), and serum g-glutamyl transferase (15). The CNS model
was calculated using the parameters of age, BMI, waistFIGURE 1 | Subject inclusion flow chart. KNHANES, Korea National Health and Nutrition Examination Survey; NAFLD, nonalcoholic fatty liver disease; FRAX,
fracture risk assessment.March 2021 | Volume 12 | Article 599339
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serum fasting glucose, serum TG, serum high density
lipoprotein-cholesterol, serum uric acid, serum aspartate
aminotransferase, and serum alanine aminotransferase (16). A
FLI of ≥60 and a CNS of ≥40 were considered indicative of
NAFLD (15, 16). The FIB-4 score was calculated using the
parameters of age, plasma platelet count, serum aspartate
aminotransferase, and serum alanine aminotransferase, with
liver fibrosis defined as scores above 1.3 (17). According to the
presence of NAFLD and liver fibrosis, it was classified into three
groups; no NAFLD group, NAFLD without liver fibrosis group,
and NAFLD with liver fibrosis group.
Sarcopenia was determined using the sarcopenia index
(sarcopenia index = total appendicular skeletal muscle mass
(kg)/BMI (kg/m2)), which involved measurement of the
appendicular skeletal muscle mass via dual-energy x-ray
absorptiometry (DEXA, QDR 4500A; Hologic, Bedford, MA).
Sarcopenia was defined as the lowest quintile for sex-specific
sarcopenia index cutoff values (< 0.807 for men) based on a
modified recommendation from the Foundation for the National
Institutes of Health (18). BMD of the femoral neck was also
examined using DEXA. BMI was calculated by dividing weight
(kg) with the square of height (m2). Smoking was defined as
current smoking. Monthly alcohol intake was defined as drinking
more than once a month during the past year.
Statistical Analysis
The characteristics of the subjects classified according to the
presence of NAFLD and liver fibrosis were expressed as the
means and standard deviations for continuous variables and as
numbers and percentages for categorical variables. A one-way
analysis of variance was used to compare the continuous
variables and a chi-squared test for categorical variables. For
post hoc analysis, the Bonferroni method was used.
Multivariate linear regression analysis was performed to
analyze the association between NAFLD with liver fibrosis and
sarcopenia and the 10-year major osteoporotic and hip fracture
probability. The regression coefficients (b) and 95% confidence
intervals (CIs) were estimated. We adjusted for multiple variables
that showed significant associations in the univariate analysis and
those based on clinical relevance. After calculating the crude b
(model 1), model 2 was adjusted for age, osteoporosis diagnosis,
fracture history, parental history of fracture, BMI, BMD of the
femoral neck, current smoking, and alcohol intake. All variables in
the linear regression analysis were examined for multi-collinearity,
and only those variables with a variance inflation factor of < 5 were
used. All statistical analyses were performed using IBM SPSS
version 25 (Armonk, NY, USA). All P values were two-tailed,
and a P value of < 0.05 was considered statistically significant.RESULTS
Subject Characteristics
A total of 2,525 subjects were included in this study (Figure 1).
Table 1 shows the demographic characteristics of the subjects
according to NAFLD and liver fibrosis. The prevalence rates ofFrontiers in Endocrinology | www.frontiersin.org 4FLI- and CNS-defined NAFLD were 20% (n = 512) and 46%
(n = 1158), respectively. The prevalence rate for NAFLD
accompanied by FIB-4–defined liver fibrosis was 11%
(n = 279) in patients with FLI-defined NAFLD and 24%
(n = 614) in patients with CNS-defined NAFLD.
In the analysis of the three groups of NAFLD defined by FLI
and CNS, age was the youngest and the 10-year hip fracture
probability was the lowest in the NAFLD without liver fibrosis
group (P < 0.001 and P = 0.001, respectively). Meanwhile, the
BMI, BMD of the femoral neck, prevalence of sarcopenia, and
alcohol intake were the lowest in the group without NAFLD (all
P < 0.001). The 10-year major osteoporotic fracture probability
was also the lowest in the group without NAFLD (P = 0.042 for
FLI-defined NAFLD; P < 0.001 for CNS-defined NAFLD).Association Between NAFLD With FIB-4
Defined Liver Fibrosis and 10-Year Major
Osteoporotic and Hip Fracture Probability
Table 2 shows the b and 95% CIs for the 10-year major
osteoporotic fracture probability according to FLI- and CNS-
defined NAFLD with FIB-4–defined liver fibrosis in the overall
cohorts. The model was adjusted for age, osteoporosis diagnosis,
previous and parental history of fracture, BMD of the femoral
neck, BMI, current smoking, and alcohol intake.
The 10-year major osteoporotic fracture probability was
higher in the FLI- and CNS-defined NAFLD without liver
fibrosis groups than that in the group without NAFLD,
although the difference was not significant. However,
compared to the no NAFLD group, the 10-year major
osteoporotic fracture probability showed significant positive
associations with the FLI-defined (b = 0.16, P = 0.002) and
CNS-defined (b = 0.20, P < 0.001) NAFLD groups with
liver fibrosis.
For the 10-year hip fracture probability, compared with the
group without NAFLD, the FLI- and CNS-defined NAFLD with
liver fibrosis groups showed significant positive associations
between the fracture probability and NAFLD with liver fibrosis
(Table 3, FLI-defined group, b = 0.04, P = 0.046; CNS-defined
group, b = 0.05, P = 0.048).Association Between NAFLD With
Significant Liver Fibrosis and 10-Year
Major Osteoporotic Fracture Probability
in the Patients With Sarcopenia
Table 4 shows the b and 95% CIs for the 10-year major
osteoporotic fracture probability according to FLI- and CNS-
defined NAFLD with FIB-defined liver fibrosis in 413 men with
sarcopenia aged ≥50 years. This model was also adjusted for age,
osteoporosis diagnosis, previous or parental history of fracture,
BMD of the femoral neck, BMI, current smoking, and
alcohol intake.
Compared with the group without NAFLD, the 10-year major
osteoporotic fracture probability was significantly higher in the
FLI-defined (b = 0.29, P = 0.003) and CNS-defined (b = 0.38,
P < 0.001) NAFLD with liver fibrosis groups.March 2021 | Volume 12 | Article 599339
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This cross-sectional study of data from the 2010–2011 KNHANES
showed that NAFLD with liver fibrosis and sarcopenia were
significantly associated with the 10-year major osteoporotic
probability in Korean men aged ≥50 years. Therefore, we
suggested that developing preventive and pharmacological
approaches for the management of NAFLD with liver fibrosis and
sarcopenia are needed as a preventive strategy for fracture (6).
Known risk factors for osteoporosis and fracture, such as poor
nutrition, excess alcohol intake, hypogonadism, and
corticosteroid use, are commonly found in patients with
chronic liver disease (8). In addition, chronic liver disease inFrontiers in Endocrinology | www.frontiersin.org 5adults (e.g., cirrhosis and advanced liver disease) is a risk factor
itself for osteoporosis and increased bone fragility (19). Several
studies reported a 10-56% reduction in BMD in adult patients
with liver fibrosis or viral liver cirrhosis (20, 21). These results
suggest that advanced liver fibrosis, which has progressed in the
absence of hepatic decompensation, has a negative effect on bone
mass and quality (22). However, there is no research on the
direct association between NAFLD with liver fibrosis and
fracture probability. Further, the pathophysiological mechanisms
by which NAFLD is associated with fractures have not been well
established (6).
Our results showed a higher risk of fracture in the group with
NAFLD with liver fibrosis, which could be explained by theTABLE 2 | Association between NAFLD with FIB-4–defined liver fibrosis and 10-year major osteoporotic fracture probability in Korean men aged ≥50 years.
FLI-defined NAFLD CNS-defined NAFLD
NAFLD (-) Fibrosis (-) NAFLD (+) Fibrosis (-) NAFLD (+) Fibrosis (+) NAFLD (-) Fibrosis (-) NAFLD (+)Fibrosis (-) NAFLD (+) Fibrosis (+)
Model 1
b Reference 0.28* 0.06 reference 0.19* 0.06
95% CI Reference 0.06–0.50 -0.15–0.27 reference 0.01–0.37 -0.11–0.24
P value Reference 0.013 0.588 reference 0.040 0.481
Model 2
b Reference 0.07 0.16* reference 0.05 0.20*
95% CI Reference -0.03–0.18 0.06–0.25 reference -0.04–0.14 0.10–0.29
P value Reference 0.150 0.002 reference 0.245 < 0.001March 2021 | VoluModel 1 was the crude model.
Model 2 was adjusted for age, osteoporosis diagnosis, fracture history, parental history of fracture, body mass index, bone mineral density of the femoral neck, current smoking, and
alcohol intake.
b is the regression coefficient, and statistical significance is represented by 95% the confidence intervals and P values.
NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis 4 calculator; FLI, fatty liver index; CNS, comprehensive NAFLD score.
*indicates statistical significance at the P value <0.05 level.TABLE 1 | Demographic characteristics of the study population.













(n = 2013) (n = 233) (n = 279) (n = 1367) (n = 544) (n = 614)
Age (years) 64.1 ± 8.6 57.35 ± 6.26a 63.71 ± 7.51b < 0.001 64.30 ± 8.83 58.67 ± 6.92a 65.63 ± 7.58a,b < 0.001
BMI (kg/m2) 22.99 ± 2.53 26.54 ± 2.30a 26.35 ± 2.62a < 0.001 22.02 ± 2.23 25.61 ± 2.18a 25.71 ± 2.27a < 0.001
BMD, femoral neck
(g/cm2)
0.74 ± 0.12 0.79 ± 0.11a 0.76 ± 0.11a < 0.001 0.72 ± 0.12 0.79 ± 0.11a 0.76 ± 0.11a,b < 0.001
Diagnosis
Osteoporosis (n, %) 27 (2.0) 3 (2.0) 2 (1.1) 0.715 23 (2.5) 5 (1.4) 4 (1.0) 0.123
Sarcopenia (n, %) 284 (21.3) 51 (32.9)a 78 (43.1)a < 0.001 163 (18.3) 99 (26.6)a 151 (37.4)a,b < 0.001
History
Fracture (n, %) 198 (14.9) 22 (14.6) 23 (13.0) 0.795 132 (14.7) 50 (14.0) 61 (15.3)b 0.890
Parental fracture
(n, %)
154 (11.4) 24 (15.6) 18 (9.9) 0.227 104 (11.4) 55 (14.9) 37 (9.0) 0.039
Smoking (n, %) 626 (31.1) 101 (43.3)a 97 (34.8) 0.001 472 (34.5) 191 (35.1) 161 (26.2)a,b < 0.001
Alcohol (n, %) 1315 (65.3) 197 (84.5)a 233 (83.5)a < 0.001 864 (63.2) 419 (77.0)a 462 (75.2)a < 0.001
10-year probability
Major fracture (%) 1.67 ± 1.49 1.94 ± 1.80a 1.75 ± 1.66 0.042 1.60 ± 1.47 1.92 ± 1.60a 1.76 ± 1.63 < 0.001
Hip fracture (%) 0.18 ± 0.31 0.11 ± 0.12a 0.19 ± 0.32b 0.001 0.18 ± 0.31 0.12 ± 0.13a 0.22 ± 0.36a,b < 0.001me 12 | ArticleData were obtained from the 2010–2011 Korean National Health and Nutrition Examination Survey.
P values were calculated using a one-way analysis of variance or chi-squared test. The Bonferroni method was used for post hoc analysis.
Continuous variables are expressed as the means and standard deviations, whereas categorical variables are expressed as numbers and percentages.
aP <0.05 by post hoc analyses when compared without NAFLD and liver fibrosis.
bP <0.05 by post hoc analyses when compared without liver fibrosis but with NAFLD.
NAFLD, nonalcoholic fatty liver disease; FLI, fatty liver index; CNS, comprehensive NAFLD score; BMI, body mass index; BMD, bone mineral density.599339
Lee et al. 10-Year Fracture Probability and NAFLDfollowing mechanisms. Insulin-like growth factor-1 is an important
driver of bone formation from mesenchymal stem cells and
promotes osteoblast survival and differentiation (23). It is
produced primarily in the liver and can lead to impaired
production during liver disease (24), likely resulting in a lower
bone turnover (25). In addition, excess fat accumulation in the liver
causes low-grade, chronic inflammation associated with the
development of bone loss and osteoporosis and a higher
likelihood of fractures (26). Increased osteoclast activity is
mediated by osteoclastogenic proinflammatory cytokines. For
example, interleukin 1 and tumor necrosis factor (TNF) are
involved in hepatic inflammation and fibrosis (8). In particular,
TNF-a can reduce trabecular and cortical bone formation by
inhibiting osteoblast differentiation and collagen secretion and by
inducing osteoblast apoptosis (27). This cytokine can also promote
trabecular and cortical bone resorption by inducing the expression
of the receptor activator of nuclear factor kappa B ligand, which
inhibits osteoclast activation and osteoblast apoptosis (28).
Sarcopenia increases the risk of falls and fractures by reducing
mobile function and increasing frailty and imbalance (10). A
systematic review reported a high prevalence of sarcopenia inFrontiers in Endocrinology | www.frontiersin.org 6men with fragility fractures and that sarcopenia was a risk factor
for fractures when accompanied by low BMD in men (29). In our
study, the association of NAFLD with liver fibrosis and 10-year
major osteoporotic fracture probability increased in the group
with sarcopenia, indicating the synergic effect of NAFLD with
liver fibrosis and sarcopenia on fracture. Although the exact
mechanism is unknown, one study of elderly patients reported
that NAFLD and sarcopenia share common pathophysiological
mechanisms that may increase the risk of fracture, including
insulin resistance and chronic low-grade inflammation (13).
Our study had some limitations. First, because this was a
cross-sectional study, causal inference cannot be drawn. Further
larger longitudinal prospective studies with multiple comparative
groups are needed to establish precise interrelationships. Second,
among the variables included in the FRAX tool (2), the history of
steroid uses and diseases that could cause secondary osteoporosis
was not included in the analysis. Therefore, the fracture risk may
have been underestimated. In addition, there are other risk
factors of fracture (e.g., physical activity, calcium/vitamin D
intake) that are not included in the FRAX tool. Therefore, further
research including additional confounding factors is needed (30).TABLE 4 | Association of NAFLD with FIB-4 defined liver fibrosis and 10-year major osteoporotic fracture probability in Korean men with sarcopenia aged ≥50 years.
NAFLD by FLI NAFLD by CNS
NAFLD (-)Fibrosis (-) NAFLD (+)Fibrosis (-) NAFLD (+)Fibrosis (+) NAFLD (-)Fibrosis (-) NAFLD (+)Fibrosis (-) NAFLD (+)Fibrosis (+)
Model 1
b Reference 0.20 0.03 Reference 0.19 0.05
95% CI Reference -0.20–0.59 -0.32–0.38 Reference -0.19–0.57 -0.31–0.40
P value Reference 0.322 0.848 Reference 0.319 0.806
Model 2
b Reference 0.09 0.29 * Reference 0.16 0.38 *
95% CI Reference -0.11–0.29 0.10–0.47 Reference -0.04–0.36 0.18–0.58
P value Reference 0.361 0.003 Reference 0.108 < 0.001March 2021 | VoluModel 1 was the crude model.
Model 2 was adjusted for age, osteoporosis diagnosis, fracture history, parental history of fracture, body mass index, bone mineral density of the femoral neck, current smoking, and
alcohol intake.
b is the regression coefficient, and statistical significance is represented by 95% confidence intervals and P values.
NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis 4 calculator; FLI, fatty liver index; CNS, comprehensive NAFLD score.
*indicates statistical significance at the P value <0.05 level.TABLE 3 | Association of NAFLD with FIB-4–defined liver fibrosis and 10-year hip fracture probability in Korean men aged ≥50 years.
NAFLD by FLI NAFLD by CNS
NAFLD (-) Fibrosis (-) NAFLD (+) Fibrosis (-) NAFLD (+)Fibrosis (+) NAFLD (-) Fibrosis (-) NAFLD (+) Fibrosis (-) NAFLD (+) Fibrosis (+)
Model 1
b Reference -0.03 0.10 * Reference -0.03 0.13 *
95% CI Reference -0.07–0.02 0.06–0.14 Reference -0.07–0.01 0.09–0.18
P value Reference 0.210 < 0.001 Reference 0.170 < 0.001
Model 2
b Reference -0.01 0.04 * Reference -0.01 0.05 *
95% CI Reference -0.05–0.03 0.001–0.08 Reference -0.05–0.03 0.001–0.09
P value Reference 0.613 0.046 Reference 0.622 0.048Model 1 was the crude model.
Model 2 was adjusted for age, osteoporosis diagnosis, fracture history, parental history of fracture, body mass index, bone mineral density of the femoral neck, current smoking, and
alcohol intake.
b is the regression coefficient, and statistical significance is represented by the 95% confidence intervals and P values.
NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis 4 calculator; FLI, fatty liver index; CNS, comprehensive NAFLD score
*indicates statistical significance at the P value <0.05 level.me 12 | Article 599339
Lee et al. 10-Year Fracture Probability and NAFLDThird, the gold standard for NAFLD diagnosis is liver biopsy.
However, NAFLD and liver fibrosis were diagnosed in our study
using FLI, CNS, and FIB-4. It should be noted, however, that liver
biopsy is not routinely used in epidemiological studies or actual
practice due to its invasiveness and potential for complication (31).
In addition, the FLI has relatively high accuracy for Koreans, with
an area under receiver operating characteristic curve (AUROC) of
0.86 (16). The CNS is a predictionmodel developed using data from
15,676 Koreans diagnosed via ultrasound. Further, its validation in
66,868 independent examination cohorts yielded a relatively high
AUROC value of 0.8-0.9 (16). FIB-4 has also been validated to be a
relatively accurate method for diagnosing NAFLD in various races
(17). Therefore, the above three diagnostic tools can be considered
reliable and easily accessible for the diagnosis of NAFLD and
liver fibrosis.
Despite these limitations, this study is valuable because to our
best knowledge, this is the first to investigate the association
between NAFLD with liver fibrosis and sarcopenia and the 10-
year fracture probability. It also provides evidence on the
potential of NAFLD with more advanced liver fibrosis and
sarcopenia as a therapeutic target for reducing the risk of
fractures. The potential impact and precise pathophysiological
mechanisms by which NAFLD with liver fibrosis and sarcopenia
is associated with the development of fracture warrants further
study (32).
In conclusion, this quantitative cross-sectional analysis of
data from the 2010–2011 KNHANES revealed that the 10-year
major osteoporotic and hip fracture probability was significantly
associated with FLI- and CNS-defined NAFLD with liver fibrosis.
Notably, this association was more profound in the subjects with
sarcopenia. These findings indicate that screening middle-aged
to elderly men who have NAFLD combined with liver fibrosisFrontiers in Endocrinology | www.frontiersin.org 7and sarcopenia for the prediction of further fracture may be a
potential preventive strategy against future fractures (32).DATA AVAILABILITY STATEMENT
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